PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing exercised Options covering 11,328 derivative securities across two transactions on 2026-09-04 at $0 per share. The transactions increased his reported derivative-security holdings to 2,936,277, giving investors the stated size, price and post-transaction ownership associated with the option exercise.
Key Highlights
- The transactions occurred on 4 September 2026 at $0 per share.
- Both transactions carried transaction code M, indicating option exercises.
- Edward Pershing owned 2,936,277 derivative securities after the transactions.
PROVECTUS BIOPHARMACEUTICALS, INC. (OTC: PVCT) CEO Edward Pershing exercised options covering 11,328 derivative securities in two transactions. The exercise price was $0 per share.
Two Transactions Covered 11,328 Derivatives
The transactions took place on 4 September 2026. The combined total across the two transactions was 11,328 derivative securities.
Post-Transaction Holding
Edward Pershing’s reported derivative-security ownership stood at 2,936,277 after the transactions. The reported holding is the post-transaction figure associated with the option exercises.
FAQs
Q: How many options did the Provectus Biopharmaceuticals CEO exercise?
A: Edward Pershing exercised options covering 11,328 derivative securities across two transactions. Both transactions occurred on 4 September 2026 at $0 per share.
Q: What was the impact of the PVCT CEO option exercise?
A: The transaction details show Edward Pershing’s derivative-security ownership at 2,936,277 after the exercise. The options were exercised at $0 per share.
Q: What does transaction code M mean in a PVCT insider transaction?
A: In this case, transaction code M appeared on both transactions involving Edward Pershing. Together, those transactions covered 11,328 derivative securities at $0 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.